Answers to frequently asked questions regarding the program “Affordable drugs” in Ukraine,which the Ministry of health will introduce in 2017
Answers to frequently asked questions regarding the program “Affordable drugs” in Ukraine, which the Ministry of health will introduce in 2017 What caused the transition to the regulation of prices for medicines and the mechanism of reimbursement of the cost of drugs? The problem of availability of medicines and improving their quality acute in Ukraine. More than 90% of medicines in Ukraine buy patients. At the same time, a significant problem is the low purchasing power of the population. Often, patients choose their own drugs, without appropriate diagnosis and not the same prevalence of disease. The "Affordable medicine" aims to change the situation in the country for the better. How is the regulation of prices for medicines in Ukraine? In most developed countries there is a practice of state regulation of prices for medicines. This allows to avoid unjustified overpricing on drugs. To ensure availability of medicines in Ukraine, the Ministry of health set a maximum reference price of the manufacturer of the drug for 21 international nepatentovannoe name (INN or the active ingredient). The reference price for medicines in Ukraine is set depending on the prices of similar medicinal product the INN's 5 neighboring countries – Poland, Slovakia, Hungary, the Czech Republic and Latvia. This is the EU, which has long been the system of price regulation for medicines and the mechanism of compensation of cost of medicines. In addition, VAT on medicines and medical devices will decrease to 2-5%, and wholesale and retail margins will be limited in the form of regressive margins. The MOH has set a maximum regression of retail markup on the sale of medicines at 15%, which will decrease with the increasing prices of medicines and is calculated on the reference price inclusive of all taxes and fees. As a result, the higher the price of the drug, the lower is the margin on this drug. Maximum wholesale markup on the sale of drugs is 5%, which is calculated on the reference price inclusive of all taxes and fees. How the mechanism of reimbursement of medicines (the reimbursement)? The mechanism of compensation of cost of drugs successfully operates in many countries and provides for the provision of free medicine to patients or a significant discount on drugs. In Ukraine, reimbursement of drugs is determined by the National list of essential medicines in 2017. It consists of recommended by the world health organization, 21 international non-proprietary name (INN or the active ingredient) for the treatment of cardiovascular diseases, bronchial asthma and diabetes mellitus II type. How will this operate in practice? 1. The patient goes to the family doctor. 2. The family doctor prescribes a recipe for the INN, form and dose. 3. A patient with a prescription sent to the pharmacy. 4. If the price of the drug at the pharmacy does not exceed a minimum price in Ukraine and MH exceeds the reference price, the patient receives the drug free of charge (full reimbursement). 5. If the price of the drug at the pharmacy is greater than the minimum price in Ukraine, but lower than the median price, the patient receives a reimbursement of funds spent for the acquisition of medicinal products in the minimum price of medicines in Ukraine (partial reimbursement). 6. If the price of drugs in the pharmacy over the median price a patient does not receive any compensation for the purchase of medicines (without reimbursement). Pharmacy gives local authorities a financial report and documentary evidence of sale of drugs that are reimbursable and gets a refund from local budgets within 15 working days. Each pharmacy institution participates in the reimbursement have to be existing is the cheapest generic (the cheapest product) and the list of reimbursement prices. Which categories of diseases are included in the program of reimbursement? Why? The mechanism of compensation of cost of medicines (reimbursement) covers cardiovascular disease, diabetes type II and bronchial asthma. The priority given to the treatment of these diseases, as they highly affect the rates of mortality or effectively treated on the outpatient basis. Cardiovascular diseases account for 65% of mortality. Only in 2015 was 22.6 million cases. Diabetes mellitus type II was in the year 2015 among the General population about 1 million people, 6 times more than diabetes mellitus type i (insulin dependent). Patients with bronchial asthma was 210 thousand in 2015, mostly children and youth. That the INN (active substance) included in the reimbursement program? CARDIOVASCULAR DISEASE: Amiodarone (Amiodarone) Amlodipine (Amlodipine) Atenolol (Atenolol) Verapamil (Verapamil) Gidrokhlorisiazit (Hydrochlorothiazide) Spironolactone (Spironolactone) Furosemide (Furosemide) Digoxin (Digoxin) Enalapril (Enalapril) Isosorbide dinitrate (Isosorbide dinitrate) Carvedilol (Carvedilol) Clopidogrel (Clopidogrel) Metoprolol (Metoprolol) Nitroglycerin (Glyceryl trinitrate) Simvastatin (Simvastatin) Bisoprolol (Bisoprolol) BRONCHIAL ASTHMA: Beclomethasone (Beclometasone) Budesonid (Budesonide) Salbutamol (Salbutamol) SUGAR DIABETES MELLITUS TYPE II: Metformin (Metformin) Gliclazide (Gliclazide) When the mechanism of compensation of cost of medicines? The mechanism of compensation of cost of medicines needed by patients, cardiovascular diseases, diabetes type II and bronchial asthma will take effect from 1 April 2017. This was reported in the Vinnytsia regional state administration.Ïåðåâåäåíî ñåðâèñîì "ßíäåêñ.Ïåðåâîä÷èê": translate.yandex.ru.
Source: http://uzinform.com.ua/
